Blog
CJC-1295 vs Ipamorelin: Different Receptors, DAC, Evidence and Research Context
Updated October 2026 • 7 min read • For qualified laboratory research education
CJC-1295 is a GHRH analog; Ipamorelin is a ghrelin-receptor agonist.
“With DAC” and “without DAC” naming must be handled carefully because it can refer to materially different pharmacokinetic designs.
Commercial pairing does not by itself prove clinical synergy.
CJC-1295 and Ipamorelin appear together so frequently in peptide catalogs that it is easy to assume they are two versions of the same mechanism. They are not. CJC-1295 is a growth-hormone-releasing hormone (GHRH) analog. Ipamorelin is a ghrelin-receptor agonist. They reach the growth-hormone axis through different receptors and have separate research histories.
That distinction is also important for SEO and research literacy because searches for “CJC-1295 vs Ipamorelin” often mix receptor pharmacology, commercial blend language and claims that are not supported by a direct combination trial.
What is CJC-1295?
CJC-1295 was developed as a long-acting analog of GHRH. In published human studies of the DAC-conjugated form, the compound prolonged growth-hormone and IGF-I responses in healthy volunteers. The “DAC” component matters because Drug Affinity Complex chemistry enables binding to albumin and materially changes pharmacokinetics.
This creates a naming problem in the commercial market: “CJC-1295” can be used loosely for materials described as with DAC or without DAC, even though the published human pharmacokinetic literature is tied to the DAC form. Researchers should therefore record the exact chemical form rather than relying on the short product name.
What is Ipamorelin?
Ipamorelin belongs to a different pharmacologic class. It is a ghrelin-receptor agonist, often described as a growth-hormone secretagogue. Its research history includes preclinical pharmacology and a randomized phase 2 study in postoperative ileus, where the biological question was not the same as the CJC-1295 healthy-volunteer endocrine studies.
The fact that both compounds can influence growth-hormone release does not mean they bind the same receptor or have the same duration, selectivity or evidence base.
CJC-1295 vs Ipamorelin at a glance
| Question | CJC-1295 | Ipamorelin |
|---|---|---|
| Primary upstream receptor | GHRH receptor | Ghrelin / GHS receptor |
| Key naming issue | With DAC vs without DAC | Compound identity and salt/form documentation |
| Human evidence | Healthy-volunteer endocrine studies of DAC form | Phase 2 postoperative ileus study plus other pharmacology |
| Combination evidence | Do not assume individual studies validate the commercial pair as one tested intervention | |
Why DAC changes the CJC-1295 conversation
The 2006 human studies reported a prolonged pharmacokinetic profile for CJC-1295 with DAC, including multi-day effects on measured endocrine markers. That is a property of the studied material. It should not be automatically transferred to every product labeled “CJC-1295,” especially where the supplier does not state whether DAC is present.
For a research buyer, the correct question is therefore not only “is this CJC-1295?” but “which CJC-1295 form is documented, and does the analytical record correspond to that form?”
Why the commercial pairing still needs its own evidence
Two compounds can converge on one physiological axis through different receptors, but that does not mean their combination has been clinically validated. Concentration ratio, timing, formulation, model and receptor dynamics can all change a combined experiment.
This is the same methodological principle explained in Peptide Blends in Laboratory Research: component evidence is not automatically blend evidence.
What researchers should verify before comparing data
- Exact CJC-1295 form, including DAC status.
- Ipamorelin identity and documented analytical result.
- Lot numbers for each component or the final blend.
- Whether a cited study used the same molecular form as the material being discussed.
- Whether the evidence is cell, animal, healthy-volunteer, clinical or combination-specific.
For analytical verification, use HPLC vs LC-MS to separate purity from identity questions.
Verify DAC status and blend composition before you order
CJC-1295 and ipamorelin are often sold together, but they act through different receptor systems and the CJC-1295 naming itself can hide an important variable: DAC status. A laboratory record that simply says “CJC + Ipamorelin” can therefore be too vague to reproduce. The procurement step should capture the exact CJC form, whether the product is a blend, the listed component amounts and the lot information.
Nerolta currently lists a CJC-1295 (no DAC) + Ipamorelin research blend, so this comparison article has a natural high-intent destination. The CTA should send the reader to the product page to verify the current composition and price, while the article keeps the receptor biology and evidence interpretation separate from the act of purchasing research material.
- Write “with DAC” or “no DAC” explicitly wherever the CJC-1295 form is known.
- For a blend, record both components and the listed presentation instead of shortening the inventory name.
- Keep blend documentation separate from papers that studied either compound alone.
Why this matters for a laboratory buyer: the research question and the procurement decision should connect cleanly. A product page should make it easy to verify identity, presentation, current price and available batch information without relying on exaggerated outcome claims. That transparency supports a faster, more defensible sourcing decision.
Before you order: make the product page part of the research record
Open the exact Nerolta listing and compare the compound name, current presentation, supplied form, storage wording, price and any available batch documentation against your laboratory SOP before purchasing. If an older article, cached result or search snippet differs from the live product page, use the live listing for the current commercial offering and the cited scientific literature for research context.
After purchase, archive the order confirmation, lot identifier and supporting documentation with the experiment record. That creates a cleaner chain from literature review to procurement and makes reorders, troubleshooting and cross-lot comparisons easier without turning marketing copy into scientific evidence.
Review the CJC-1295 (no DAC) + Ipamorelin research blend
Check Nerolta’s current product composition, presentation and price before matching the material to your laboratory protocol.
View CJC-1295 + IpamorelinBrowse all research compounds
Frequently asked research questions
Are CJC-1295 and Ipamorelin the same type of peptide?
No. They are structurally and pharmacologically distinct and act through different receptors.
Does all “CJC-1295” have DAC?
No. Commercial naming is inconsistent. The exact form should be stated and documented rather than inferred from the short name.
Has the CJC-1295 + Ipamorelin pairing been proven by a direct human combination trial?
The individual compounds have separate published records. Researchers should not treat those separate records as proof of a specific combined formulation.
What the published human studies actually belong to
The most cited human CJC-1295 paper was not a trial of a CJC-1295/Ipamorelin blend. It was a randomized, placebo-controlled study of CJC-1295 in healthy adults that measured pharmacokinetics, growth hormone and IGF-I. A companion paper examined whether pulsatile growth-hormone secretion persisted after CJC-1295 exposure. Those studies help define the DAC-form evidence base, but they do not establish the behavior of an unlabeled “CJC” product or a two-compound mixture.
Ipamorelin’s best-known human development record is different. A randomized proof-of-concept phase 2 study evaluated the ghrelin-receptor agonist in patients after bowel resection, with postoperative ileus as the clinical problem. That program therefore answers a different biological question from the healthy-volunteer endocrine studies of CJC-1295. The existence of human data for both molecules should not be summarized as “the combination has human evidence.”
Why receptor convergence is not proof of synergy
It is tempting to reason that two upstream signals reaching the same endocrine axis must create a predictable additive or synergistic result. Biology is rarely that simple. Receptor occupancy, feedback loops, timing, desensitization, assay window and model selection can all change the observed response. “Different receptors” is a mechanistic rationale for studying a combination, not proof of what the combination will do.
For rigorous research, synergy should be demonstrated experimentally using a design that can separate the effect of component A, component B and the combination. Without that structure, an observed response in a blend cannot be assigned confidently to interaction rather than one component alone.
Documentation questions that matter for a CJC-1295/Ipamorelin product
- Does the label specify whether the CJC-1295 component contains DAC?
- Are both component identities listed clearly rather than hidden behind a blend nickname?
- Does the lot-specific documentation identify the same formulation that is on the vial?
- Is the reported HPLC result for the final blend, individual components, or both?
- Is orthogonal identity evidence available when the supplier claims a specific molecular form?
These questions turn a vague catalog name into a reproducible laboratory record and help prevent literature from being attached to the wrong molecular form.
Explore the CJC-1295 + Ipamorelin research listing
Review Nerolta Labs product information and verify the exact form, presentation and available batch documentation before designing laboratory work.
References & further reading
- Prolonged stimulation of GH and IGF-I by CJC-1295 in healthy adults — JCEM
- Pulsatile GH secretion during CJC-1295 stimulation — JCEM
- Randomized phase 2 study of Ipamorelin in postoperative ileus
- FDA Pharmacy Compounding Advisory Committee: CJC-1295-related substances
